Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

BACKGROUND: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons to preclude the initiation of durvalumab in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanzawa, Shigeru, Makiguchi, Tomonori, Tasaka, Sadatomo, Inaba, Megumi, Ochiai, Ryosuke, Nakamura, Junya, Inoue, Koji, Kishikawa, Takayuki, Nakashima, Masanao, Fujiwara, Keiichi, Kohyama, Tadashi, Ishida, Hiroo, Kuyama, Shoichi, Miyazawa, Naoki, Nakamura, Tomomi, Miyawaki, Hiroshi, Oda, Naohiro, Ishikawa, Nobuhisa, Morinaga, Ryotaro, Kusaka, Kei, Miyamoto, Yosuke, Yokoyama, Toshihide, Matsumoto, Chiaki, Tsuda, Takeshi, Ushijima, Sunao, Shibata, Kazuhiko, Shibayama, Takuo, Bessho, Akihiro, Kaira, Kyoichi, Misumi, Toshihiro, Shiraishi, Kenshiro, Matsutani, Noriyuki, Seki, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340896/
https://www.ncbi.nlm.nih.gov/pubmed/35923924
http://dx.doi.org/10.1177/17588359221116603

Ejemplares similares

Ejemplares similares